- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05630833
A Study to Investigate the Efficacy and Safety With Gepotidacin in Japanese Female Participants With Uncomplicated Urinary Tract Infection (Acute Cystitis) (EAGLE-J)
February 9, 2023 updated by: GlaxoSmithKline
A Phase III, Multicenter, Randomized, Active Reference, Double Blind, Double-dummy Study in Japanese Female Participants to Evaluate the Efficacy and Safety of Gepotidacin in the Treatment of Uncomplicated Urinary Tract Infection (Acute Cystitis)
The purpose of this study is to evaluate the consistency of therapeutic response of gepotidacin at the Test of cure (TOC) Visit (Days 10 to 13) in female participants with acute uncomplicated cystitis with qualifying bacterial uropathogen(s) at baseline that all are susceptible to nitrofurantoin in Japan, with that from global studies (Studies 204989 [NCT04020341] and 212390 [NCT04187144]).
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
300
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Ibaraki, Japan, 300-0062
- Recruiting
- GSK Investigational Site
-
Principal Investigator:
- Masaru Mori
-
Osaka, Japan, 534-0024
- Recruiting
- GSK Investigational Site
-
Principal Investigator:
- Kenji Sugimoto
-
Saitama, Japan, 352-0001
- Recruiting
- GSK Investigational Site
-
Principal Investigator:
- Hiroyuki Kusuyama
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
12 years and older (ADULT, OLDER_ADULT, CHILD)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- The participant has a body weight >=40 kilograms (kg).
- The participant has 2 or more of the following clinical signs and symptoms of acute cystitis with onset less than (<) 96 hours prior to study entry: dysuria, frequency, urgency, or lower abdominal pain.
- The participant has nitrite or pyuria (greater than [>]15 white blood cell [WBC]/high-power field [HPF] or the presence of 3 plus (+) /large leukocyte esterase) from a pretreatment clean-catch midstream urine sample based on local laboratory procedures.
- The participant is capable of giving signed informed consent/assent.
Exclusion Criteria:
- The participant resides in a nursing home or dependent care type facility.
- The participant has a body mass index >=40.0 kilogram per meter square (kg/m^2) or a body mass index >=35.0 kg/m^2 and is experiencing obesity-related health conditions such as uncontrolled high blood pressure or uncontrolled diabetes.
- The participant is immunocompromised or has altered immune defenses that may predispose the participant to a higher risk of treatment failure and/or complications.
The participant has any of the following:
- Poorly controlled asthma or chronic obstructive pulmonary disease; Acute severe pain; Active peptic ulcer disease; Parkinson disease; Myasthenia gravis; a history of seizure disorder requiring medications for control (this does not include a history of childhood febrile seizures); Or
- Known acute porphyria.
- Any surgical or medical condition (active or chronic) that may interfere with drug absorption, distribution, metabolism, or excretion of the study intervention.
- The participant has a known glucose-6-phosphate dehydrogenase deficiency.
- The participant, in the judgment of the investigator, would not be able or willing to comply with the protocol or complete study follow-up.
- The participant has acute uncomplicated cystitis that is known or suspected to be due to fungal, parasitic, or viral pathogens; or known or suspected to be due to Pseudomonas aeruginosa or Enterobacterales (other than E. coli) as the contributing pathogen.
- The participant has symptoms known or suspected to be caused by another disease process, such as asymptomatic bacteriuria, overactive bladder, chronic incontinence, or chronic interstitial cystitis, that may interfere with the clinical efficacy assessments or preclude complete resolution of acute cystitis symptoms.
- The participant has an anatomical or physiological anomaly that predisposes the participant to UTIs or may be a source of persistent bacterial colonization, including calculi, obstruction or stricture of the urinary tract, primary renal disease (e.g., polycystic renal disease), or neurogenic bladder, or the participant has a history of anatomical or functional abnormalities of the urinary tract (e.g., chronic vesicoureteral reflux, detrusor insufficiency).
- The participant has an indwelling catheter, nephrostomy, ureter stent, or other foreign material in the urinary tract.
- The participant who, in the opinion of the investigator, has an otherwise complicated UTI, an active upper UTI (e.g., pyelonephritis, urosepsis), signs and symptom onset >=96 hours before study entry, or a temperature >=38 Degrees Celsius [°C], flank pain, chills, or any other manifestations suggestive of upper UTI.
- The participant has known anuria, oliguria, or significant impairment of renal function (creatinine clearance <60 milliliters per minute (mL/min) or clinically significant elevated serum creatinine as determined by the investigator).
- The participant presents with vaginal discharge at Baseline (e.g., suspected sexually transmitted disease).
- The participant has congenital long QT syndrome or known prolongation of the corrected QT (QTc) interval.
- The participant has uncompensated heart failure.
- The participant has severe left ventricular hypertrophy.
- The participant has a family history of QT prolongation or sudden death.
- The participant has a recent history of vasovagal syncope or episodes of symptomatic bradycardia or brady arrhythmia within the last 12 months.
- The participant is taking QT-prolonging drugs or drugs known to increase the risk of torsades de pointes (TdP) per the www.crediblemeds.org. "Known Risk of TdP" category at the time of her Baseline Visit, which cannot be safely discontinued from the Baseline Visit to the TOC Visit; or the participant is taking a strong cytochrome P450 enzyme 3A4 (CYP3A4) inhibitor.
- For any participant >=12 to <18 years of age, the participant has an abnormal ECG reading at Baseline.
- The participant has a QTc >450 msec or a QTc >480 msec for participants with bundle branch block.
- The participant has a documented or recent history of uncorrected hypokalemia within the past 3 months.
- The participant has a known alanine aminotransferase (ALT) value >2 times upper limit of normal (ULN).
- The participant has a known total bilirubin value >1.5 times ULN (isolated bilirubin >1.5 times ULN is acceptable if bilirubin is fractionated and direct bilirubin <35 percent [%]).
- The participant has cirrhosis or current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, or persistent jaundice.
- The participant has a previous history of cholestatic jaundice/hepatic dysfunction associated with nitrofurantoin.
- The participant has received treatment with other systemic antimicrobials or systemic antifungals within 1 week before study entry.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Gepotidacin + Placebo
|
Placebo will be administered.
Gepotidacin will be administered.
|
ACTIVE_COMPARATOR: Nitrofurantoin + Placebo
|
Placebo will be administered.
Nitrofurantoin will be administered.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with therapeutic response (combined per participant clinical and microbiological response) at the TOC Visit
Time Frame: Days 10 to 13
|
A therapeutic success refers to participants who have been deemed both a "microbiological success" (reduction of all qualifying bacterial uropathogens [greater than or equal to {>=}10^5 colony-forming units per milliliter {CFU/mL}] recovered at Baseline to less than (<)10^3 CFU/mL as observed on quantitative urine culture without the participant receiving other systemic antimicrobials at the TOC Visit) and a "clinical success" (resolution of signs and symptoms of acute cystitis present at Baseline [and no new signs and symptoms] without the participant receiving other systemic antimicrobials at the TOC Visit).
All other combinations (other than clinical success + microbiological success) are deemed failures for therapeutic response.
|
Days 10 to 13
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with therapeutic response to gepotidacin compared to nitrofurantoin at the TOC Visit
Time Frame: Days 10 to 13
|
Days 10 to 13
|
|
Number of participants with clinical outcome and response at the TOC visit
Time Frame: Days 10 to 13
|
Clinical success (response) is defined as clinical resolution.
Clinical resolution (outcome) is defined as resolution of signs and symptoms of acute cystitis present at Baseline (and no new signs and symptoms) without the participant receiving other systemic antimicrobials.
|
Days 10 to 13
|
Number of participants with per participant microbiological outcome and response at the TOC visit
Time Frame: Days 10 to 13
|
Participant-level microbiological success (response) is defined as microbiological eradication.
Microbiological eradication (outcome) is defined as reduction of all qualifying bacterial uropathogens [>=10^5 CFU/mL] recovered at Baseline to <10^3 CFU/mL as observed on quantitative urine culture without the participant receiving other systemic antimicrobials.
|
Days 10 to 13
|
Number of participants with therapeutic response in female participants with acute uncomplicated cystitis who have qualifying uropathogen(s) resistant to two or more specific classes of antimicrobials
Time Frame: Days 10 to 13
|
Days 10 to 13
|
|
Number of participants with clinical outcome and response in female participants with acute uncomplicated cystitis who have qualifying uropathogen(s) resistant to two or more specific classes of antimicrobials
Time Frame: Days 10 to 13
|
Days 10 to 13
|
|
Number of participants with microbiological outcome and response in female participants with acute uncomplicated cystitis who have qualifying uropathogen(s) resistant to two or more specific classes of antimicrobials
Time Frame: Days 10 to 13
|
Days 10 to 13
|
|
Number of participants with Investigator assessment of clinical response at the TOC Visit
Time Frame: Days 10 to 13
|
Days 10 to 13
|
|
Number of participants with Treatment-Emergent Adverse Events (TEAEs)
Time Frame: Up to Day 31
|
Up to Day 31
|
|
Number of participants with Serious Adverse Events (SAEs)
Time Frame: Up to Day 31
|
Up to Day 31
|
|
Number of participants with Adverse Events of Special Interest (AESIs)
Time Frame: Up to Day 31
|
Up to Day 31
|
|
Change from baseline in hematology parameters: neutrophil count, lymphocyte count, monocyte count, eosinophil count, basophil count and platelet count (Giga cells per liter)
Time Frame: Baseline, On-Therapy (Days 2 to 4), and TOC (Days 10 to 13)
|
Baseline, On-Therapy (Days 2 to 4), and TOC (Days 10 to 13)
|
|
Change from baseline in hematology parameter: Red Blood Cell (RBC) count (Trillion cells per liter)
Time Frame: Baseline, On-Therapy (Days 2 to 4), and TOC (Days 10 to 13)
|
Baseline, On-Therapy (Days 2 to 4), and TOC (Days 10 to 13)
|
|
Change from baseline in hematology parameter: Hemoglobin (Hb) (Grams per liter)
Time Frame: Baseline, On-Therapy (Days 2 to 4), and TOC (Days 10 to 13)
|
Baseline, On-Therapy (Days 2 to 4), and TOC (Days 10 to 13)
|
|
Change from baseline in hematology parameter: Hematocrit (Proportion of red blood cells in blood)
Time Frame: Baseline, On-Therapy (Days 2 to 4), and TOC (Days 10 to 13)
|
Baseline, On-Therapy (Days 2 to 4), and TOC (Days 10 to 13)
|
|
Change from baseline in hematology parameter: Mean Corpuscular Volume (MCV) (Femtoliters)
Time Frame: Baseline, On-Therapy (Days 2 to 4), and TOC (Days 10 to 13)
|
Baseline, On-Therapy (Days 2 to 4), and TOC (Days 10 to 13)
|
|
Change from baseline in hematology parameter: Mean Corpuscular Hemoglobin (MCH) (Picograms)
Time Frame: Baseline, On-Therapy (Days 2 to 4), and TOC (Days 10 to 13)
|
Baseline, On-Therapy (Days 2 to 4), and TOC (Days 10 to 13)
|
|
Change from baseline in clinical chemistry parameters: Blood urea nitrogen [BUN], glucose [non-fasting], calcium, chloride, sodium, magnesium, phosphate, and potassium levels (Millimoles per liter)
Time Frame: Baseline, On-Therapy (Days 2 to 4), and TOC (Days 10 to 13)
|
Baseline, On-Therapy (Days 2 to 4), and TOC (Days 10 to 13)
|
|
Change from baseline in clinical chemistry parameters: Total bilirubin, direct bilirubin and creatinine levels (Micromoles per liter)
Time Frame: Baseline, On-Therapy (Days 2 to 4), and TOC (Days 10 to 13)
|
Baseline, On-Therapy (Days 2 to 4), and TOC (Days 10 to 13)
|
|
Change from baseline in clinical chemistry parameters: albumin and total protein levels (Gram per liter)
Time Frame: Baseline, On-Therapy (Days 2 to 4), and TOC (Days 10 to 13)
|
Baseline, On-Therapy (Days 2 to 4), and TOC (Days 10 to 13)
|
|
Change from baseline in clinical chemistry parameters: Aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase levels (International units per liter)
Time Frame: Baseline, On-Therapy (Days 2 to 4), and TOC (Days 10 to 13)
|
Baseline, On-Therapy (Days 2 to 4), and TOC (Days 10 to 13)
|
|
Change from Baseline in systolic blood pressure (SBP) and diastolic blood pressure (DBP) (Millimeters of mercury [mmHg])
Time Frame: Baseline, On-Therapy (Days 2 to 4), and TOC (Days 10 to 13)
|
Baseline, On-Therapy (Days 2 to 4), and TOC (Days 10 to 13)
|
|
Change from baseline in pulse rate (Beats per minute)
Time Frame: Baseline, On-Therapy (Days 2 to 4), and TOC (Days 10 to 13)
|
Baseline, On-Therapy (Days 2 to 4), and TOC (Days 10 to 13)
|
|
Change from baseline in body temperature (Degrees Celsius)
Time Frame: Baseline, On-Therapy (Days 2 to 4), and TOC (Days 10 to 13)
|
Baseline, On-Therapy (Days 2 to 4), and TOC (Days 10 to 13)
|
|
Change from baseline in heart rate (Beats per minute)
Time Frame: Baseline, On-Therapy (Days 2 to 4), and TOC (Days 10 to 13)
|
Baseline, On-Therapy (Days 2 to 4), and TOC (Days 10 to 13)
|
|
Change from baseline in electrocardiogram parameters: PR Interval, QRS Duration, QT Interval, QT interval corrected for heart rate according Fridericia's formula (QTcF) and Bazett's formula (QTcB) (Milliseconds [msec])
Time Frame: Baseline, On-Therapy (Days 2 to 4), and TOC (Days 10 to 13)
|
Baseline, On-Therapy (Days 2 to 4), and TOC (Days 10 to 13)
|
|
Plasma concentration of gepotidacin
Time Frame: Up to Day 4
|
Up to Day 4
|
|
Urine concentration of gepotidacin
Time Frame: Up to Day 4
|
Up to Day 4
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
January 11, 2023
Primary Completion (ANTICIPATED)
September 11, 2023
Study Completion (ANTICIPATED)
October 9, 2023
Study Registration Dates
First Submitted
November 23, 2022
First Submitted That Met QC Criteria
November 23, 2022
First Posted (ACTUAL)
November 30, 2022
Study Record Updates
Last Update Posted (ACTUAL)
February 10, 2023
Last Update Submitted That Met QC Criteria
February 9, 2023
Last Verified
February 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 214144
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal.
Details on GSK's data sharing criteria can be found at: https://www.gsk.com/en-gb/innovation/trials/data-transparency/
IPD Sharing Time Frame
Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.
IPD Sharing Access Criteria
Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place.
Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Urinary Tract Infections
-
GlaxoSmithKlineCompletedInfections, Urinary TractEgypt
-
University of WashingtonNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Completed
-
Iterum Therapeutics, International LimitedCompletedComplicated Urinary Tract InfectionsUnited States, Estonia, Hungary, Georgia, Latvia
-
Shandong Branden Med.Device Co.,LtdTerminatedUrinary Tract Infection | Urinary CathetersChina
-
Inmunotek S.L.CompletedUrinary Tract Infection BacterialSpain, United Kingdom
-
AbbottCompletedUrinary Tract Infections (UTIs)Pakistan
-
Hospital del Río HortegaCompletedUrinary Tract Infection
-
Assaf-Harofeh Medical CenterNanovibronixUnknown
-
Bergaliden BarnavårdscentralCompleted
-
Newcastle-upon-Tyne Hospitals NHS TrustCambridge University Hospitals NHS Foundation Trust; University of Southampton and other collaboratorsCompletedUrinary Tract Infections, RecurrentUnited Kingdom
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States